Literature DB >> 23233093

Ovarian cancer : making its own rules-again.

Elise C Kohn, Jean Hurteau.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23233093      PMCID: PMC3553273          DOI: 10.1002/cncr.27833

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


× No keyword cloud information.
  26 in total

1.  Improved survival with vemurafenib in melanoma with BRAF V600E mutation.

Authors:  Paul B Chapman; Axel Hauschild; Caroline Robert; John B Haanen; Paolo Ascierto; James Larkin; Reinhard Dummer; Claus Garbe; Alessandro Testori; Michele Maio; David Hogg; Paul Lorigan; Celeste Lebbe; Thomas Jouary; Dirk Schadendorf; Antoni Ribas; Steven J O'Day; Jeffrey A Sosman; John M Kirkwood; Alexander M M Eggermont; Brigitte Dreno; Keith Nolop; Jiang Li; Betty Nelson; Jeannie Hou; Richard J Lee; Keith T Flaherty; Grant A McArthur
Journal:  N Engl J Med       Date:  2011-06-05       Impact factor: 91.245

2.  Diagnosis of ovarian carcinoma cell type is highly reproducible: a transcanadian study.

Authors:  Martin Köbel; Steve E Kalloger; Patricia M Baker; Carol A Ewanowich; Jocelyne Arseneau; Viktor Zherebitskiy; Soran Abdulkarim; Samuel Leung; Máire A Duggan; Dan Fontaine; Robin Parker; David G Huntsman; C Blake Gilks
Journal:  Am J Surg Pathol       Date:  2010-07       Impact factor: 6.394

Review 3.  Ovarian low-grade and high-grade serous carcinoma: pathogenesis, clinicopathologic and molecular biologic features, and diagnostic problems.

Authors:  Russell Vang; Ie-Ming Shih; Robert J Kurman
Journal:  Adv Anat Pathol       Date:  2009-09       Impact factor: 3.875

Review 4.  Oncogenic mutations as predictive factors in colorectal cancer.

Authors:  A Lièvre; H Blons; P Laurent-Puig
Journal:  Oncogene       Date:  2010-04-12       Impact factor: 9.867

Review 5.  Therapeutic implications of resistance to molecular therapies in metastatic colorectal cancer.

Authors:  A Sartore-Bianchi; K Bencardino; A Cassingena; F Venturini; C Funaioli; T Cipani; A Amatu; L Pietrogiovanna; R Schiavo; F Di Nicolantonio; S Artale; A Bardelli; S Siena
Journal:  Cancer Treat Rev       Date:  2010-11       Impact factor: 12.111

6.  Inhibition of mutated, activated BRAF in metastatic melanoma.

Authors:  Keith T Flaherty; Igor Puzanov; Kevin B Kim; Antoni Ribas; Grant A McArthur; Jeffrey A Sosman; Peter J O'Dwyer; Richard J Lee; Joseph F Grippo; Keith Nolop; Paul B Chapman
Journal:  N Engl J Med       Date:  2010-08-26       Impact factor: 91.245

Review 7.  BRAFV600E: implications for carcinogenesis and molecular therapy.

Authors:  Emma R Cantwell-Dorris; John J O'Leary; Orla M Sheils
Journal:  Mol Cancer Ther       Date:  2011-03       Impact factor: 6.261

8.  Integrated genomic analyses of ovarian carcinoma.

Authors: 
Journal:  Nature       Date:  2011-06-29       Impact factor: 49.962

9.  High throughput interrogation of somatic mutations in high grade serous cancer of the ovary.

Authors:  Ursula A Matulonis; Michelle Hirsch; Emanuele Palescandolo; Eejung Kim; Joyce Liu; Paul van Hummelen; Laura MacConaill; Ronny Drapkin; William C Hahn
Journal:  PLoS One       Date:  2011-09-08       Impact factor: 3.240

Review 10.  Biomarkers predicting clinical outcome of epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer.

Authors:  Salvatore Siena; Andrea Sartore-Bianchi; Federica Di Nicolantonio; Julia Balfour; Alberto Bardelli
Journal:  J Natl Cancer Inst       Date:  2009-09-08       Impact factor: 13.506

View more
  5 in total

1.  Rac1 expression in epithelial ovarian cancer: effect on cell EMT and clinical outcome.

Authors:  Ruobing Leng; Gang Liao; Haixia Wang; Jun Kuang; Liangdan Tang
Journal:  Med Oncol       Date:  2015-01-14       Impact factor: 3.064

2.  The role of miR-200a in mammalian epithelial cell transformation.

Authors:  Lindsey E Becker; Apana Agha L Takwi; Zhongxin Lu; Yong Li
Journal:  Carcinogenesis       Date:  2014-09-19       Impact factor: 4.944

Review 3.  Clinical implications of using molecular diagnostics for ovarian cancers.

Authors:  E C Kohn; S Romano; J-M Lee
Journal:  Ann Oncol       Date:  2013-12       Impact factor: 32.976

4.  Ambivalent role of pFAK-Y397 in serous ovarian cancer--a study of the OVCAD consortium.

Authors:  Stefanie Aust; Katharina Auer; Anna Bachmayr-Heyda; Carsten Denkert; Jalid Sehouli; Ioana Braicu; Sven Mahner; Sandrina Lambrechts; Ignace Vergote; Christoph Grimm; Reinhard Horvat; Dan Cacsire Castillo-Tong; Robert Zeillinger; Dietmar Pils
Journal:  Mol Cancer       Date:  2014-03-21       Impact factor: 27.401

Review 5.  BRAF gene: From human cancers to developmental syndromes.

Authors:  Muhammad Ramzan Manwar Hussain; Mukhtiar Baig; Hussein Sheik Ali Mohamoud; Zaheer Ulhaq; Daniel C Hoessli; Ghaidaa Siraj Khogeer; Ranem Radwan Al-Sayed; Jumana Yousuf Al-Aama
Journal:  Saudi J Biol Sci       Date:  2014-10-23       Impact factor: 4.219

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.